Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Assets Average (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Assets Average for 11 consecutive years, with $292.4 million as the latest value for Q1 2026.

  • For Q1 2026, Assets Average fell 30.72% year-over-year to $292.4 million; the TTM value through Mar 2026 reached $292.4 million, down 30.72%, while the annual FY2025 figure was $365.7 million, 1.17% down from the prior year.
  • Assets Average hit $292.4 million in Q1 2026 for Cartesian Therapeutics, down from $334.5 million in the prior quarter.
  • Across five years, Assets Average topped out at $445.2 million in Q4 2024 and bottomed at $122.8 million in Q3 2023.
  • Average Assets Average over 5 years is $272.9 million, with a median of $292.4 million recorded in 2026.
  • Year-over-year, Assets Average crashed 32.97% in 2023 and then soared 227.06% in 2024.
  • Cartesian Therapeutics' Assets Average stood at $172.1 million in 2022, then grew by 19.45% to $205.5 million in 2023, then skyrocketed by 116.58% to $445.2 million in 2024, then decreased by 24.85% to $334.5 million in 2025, then decreased by 12.6% to $292.4 million in 2026.
  • According to Business Quant data, Assets Average over the past three periods came in at $292.4 million, $334.5 million, and $380.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.